img1Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development a platform of novel compounds in oncology and biodefense. The company develops a class of catalytic antioxidant compounds as a medical countermeasure against biological, chemical, and radiological weapons, as well as for diseases and disorders of the central nervous system, respiratory system, autoimmune system, and oncology. Its lead compound, AEOL 10150, which completed two Phase I clinical trials is developed against the pulmonary sub-syndrome of acute radiation syndrome, as well as the gastrointestinal sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure (MCM) for exposure to chemical vesicants such as chlorine gas, sulfur mustard gas, and nerve agents. The company also develops AEOL 11207 for treatment of epilepsy and Parkinson’s disease and epilepsy; and AEOL 10171 as a potential MCM for acute radiation syndrome. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.